logo-loader
viewShield Therapeutics PLC

Shield Therapeutics 'very active' on US partnering discussions with significant interest

Shield Therapeutics (LON:STX) CEO Tim Watts tells Proactive London's Andrew Scott they've seen very little disruption from the coronavirus pandemic on plans to commercialise its iron deficiency drug Feraccru.

He says talks to find a partner for the product in the US are ongoing with significant interest from a range of companies.

Quick facts: Shield Therapeutics PLC

Price: 85.5 GBX

LSE:STX
Market: LSE
Market Cap: £100.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics PLC: Proactive One2One Virtual Event

Shield Therapeutics PLC's (LON:STX) Tim Watts pitches the company to investors at the Proactive One2One Virtual Event. Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Group’s lead...

1 month ago

2 min read